Article
Microbiology
Aipeng Mao, Weigang Zhao, Yuhang Zhu, Fantao Kong, Danyang Chen, Huazhe Si, Chao Xu
Summary: This study analyzed the clinical symptoms and pathogenesis of a DSS-induced canine IBD model and evaluated the restorative effect of ginsenoside. The findings revealed that dogs with IBD exhibited decreased mental state, disrupted colonic tissue structure, and reduced diversity of the colonic mucosal bacterial community. Ginsenoside treatment improved these symptoms and reversed the relative abundance of some bacterial communities.
Review
Biochemistry & Molecular Biology
Jing Peng, Hao Li, Oladejo Ayodele Olaolu, Saber Ibrahim, Sally Ibrahim, Shengyi Wang
Summary: Inflammatory bowel disease (IBD) is a condition that affects the entire gastrointestinal tract and mucosal layer, causing intestinal damage and dysfunction. Current treatments for IBD, such as monoclonal antibodies and synthetic medications, have potential side effects and long-term complications. Studies have shown that organic macromolecules from plants and animals have anti-IBD effects, including altering enzyme function, reducing oxidative stress, and inhibiting inflammation. This review focuses on the protective effects of natural products on intestinal barrier integrity and tight junction protein expression and remodeling, providing insights for the development of natural products for IBD treatment.
Review
Pharmacology & Pharmacy
Miguel Camba-Gomez, Laura Arosa, Oreste Gualillo, Javier Conde-Aranda
Summary: Despite the benefits of current therapeutic options, there is a need for novel pharmacological targets to improve the treatment of inflammatory bowel disease (IBD). Chemokine and chemokine receptors have emerged as appealing options, as they regulate leukocyte trafficking and other processes related to intestinal inflammation development.
DRUG DISCOVERY TODAY
(2022)
Review
Gastroenterology & Hepatology
Hannah Gordon, Beverley Rodger, James O. Lindsay, Andrew J. Stagg
Summary: Targeting leukocyte trafficking has been a significant therapeutic advance in managing inflammatory bowel disease (IBD), but its efficacy is limited and it can cause significant side effects. This article reviews the mechanisms of T cell recruitment and residence, highlighting the complexity and plasticity of the intestinal immune response.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Medicine, Research & Experimental
Fei Yang, Xiaoqiang Zhu, Liu Li, Yanping Wang, Qing Xie, Yu Cao, Yunhui Yu, Minjie Zhang, Dong Li, Ling Li, Zhongtian Liu, Biyan Zhang, Zijun Chen, Shiping Deng, Yunsen Li
Summary: The study found that SDH can promote the expression of tight junction proteins, protect the integrity and permeability of the epithelial barrier, and may serve as a novel therapeutic agent for the treatment of IBD.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Gastroenterology & Hepatology
Masaaki Higashiyama, Ryota Hokaria
Summary: This paper provides an overview of the current treatment status and future prospects for inflammatory bowel disease (IBD). While there are already many new treatment options available, there is still a need for better efficacy and fewer side effects in some refractory cases. Promising treatments with new perspectives are expected to emerge in the future.
Article
Gastroenterology & Hepatology
Kendra L. Francis, Kimberly M. Alonge, Maria Cristina Pacheco, Shannon J. Hu, Cody A. Krutzsch, Gregory J. Morton, Michael W. Schwartz, Jarrad M. Scarlett
Summary: This study found that diabetes worsened clinical and histopathologic outcomes of colitis in mice with diet-induced obesity, possibly due to hyperglycemia-induced intestinal barrier dysfunction. These findings suggest that effective diabetes management may decrease the clinical severity of inflammatory bowel disease.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Medicine, Research & Experimental
Zelin Feng, Guangbo Kang, Jiewen Wang, Xingjie Gao, Xiaoli Wang, Yulin Ye, Limin Liu, Jingwen Zhao, Xinjuan Liu, He Huang, Xiaocang Cao
Summary: Emerging biologics and small-molecule drugs have changed the treatment landscape of inflammatory bowel disease (IBD), but dual-targeted therapy (DTT) shows promise in overcoming treatment limitations. However, limited data on efficacy, safety, and mechanisms of DTT for Crohn's disease and ulcerative colitis exist. This review summarizes current data on novel targeted drugs for refractory IBD, categorizes therapeutic agents based on targets, and proposes mechanisms of DTT to aid clinical decision-making and future drug development.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Gastroenterology & Hepatology
Clara Abraham, Maria T. Abreu, Jerrold R. Turner
Summary: This review focuses on the role of pattern recognition receptors in the inflammatory response and regulation of epithelial barrier in inflammatory bowel disease. It explores the cytokine networks that contribute to inflammation, regulation of paracellular permeability, epithelial damage, up-regulation of epithelial proliferation, and restitutive processes. Patient samples are used in studies and potential pathways for a more comprehensive treatment approach for patients with inflammatory bowel disease are speculated.
Review
Cell Biology
Matthew Luzentales-Simpson, Yvonne C. F. Pang, Ada Zhang, James A. Sousa, Laura M. Sly
Summary: Inflammatory bowel diseases are characterized by chronic inflammation along the gastrointestinal tract due to excessive leukocyte infiltration. Current treatments include aminosalicylates, corticosteroids, immunosuppressants, and biologics such as anti-TNF antibodies, although some patients may become unresponsive to anti-TNF therapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Food Science & Technology
Shen Zhuang, Ke Ming, Ning Ma, Jinrui Sun, Dehai Wang, Mingxing Ding, Yi Ding
Summary: A specific polysaccharide fraction (POPZ) from Portulaca oleracea L. was found to inhibit LPS-induced barrier injury and inflammatory responses in porcine intestinal epithelial monolayer, possibly through inactivating TLR4/NF-κB pathway and activating EGF/EGFR pathway.
JOURNAL OF FUNCTIONAL FOODS
(2022)
Article
Food Science & Technology
Wing-Yan Wong, Brandon Dow Chan, Tsz-Wing Leung, ManXin Chen, William Chi-Shing Tai
Summary: An altered gut microbiota is observed in inflammatory bowel disease (IBD), and maintaining and modulating the gut microbiome through prebiotics, probiotics, and synbiotics may have beneficial effects on health and potential therapeutic effects in IBD. Pre, Pro, and Syn consumption led to reductions in plasma IL-6 levels, increased intestinal occludin expression, modulation of gut microbiota, improved gut integrity, upregulation of anti-inflammatory cytokines, and suppression of pro-inflammatory mediators, suggesting their potential in treating IBD.
JOURNAL OF FUNCTIONAL FOODS
(2022)
Article
Pharmacology & Pharmacy
Sonia Shastri, Tanvi Shinde, Krystel L. Woolley, Jason A. Smith, Nuri Gueven, Rajaraman Eri
Summary: Ulcerative colitis (UC) is characterized by chronic, relapsing, idiopathic, and multifactorial colon inflammation. Recent evidence suggests that mitochondrial dysfunction plays a critical role in the onset and recurrence of this disease. The study found that UTA77 could be a promising novel therapeutic approach for the treatment of human UC, as it improved UC symptoms and pathology in mouse models.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Nathan Calzadilla, Shane M. M. Comiskey, Pradeep K. K. Dudeja, Seema Saksena, Ravinder K. K. Gill, Waddah A. A. Alrefai
Summary: Bile acids play a critical role in lipid and fat-soluble vitamin digestion and absorption, but they also act as signaling molecules. Disturbances in bile acid homeostasis can contribute to the development of Inflammatory Bowel Diseases (IBD). Studies have shown that different bile acids have different effects on the inflammatory response and intestinal permeability, suggesting a potential link between bile acid changes and the development of IBD.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Nutrition & Dietetics
Olga Kaczmarczyk, Agnieszka Dabek-Drobny, Agnieszka Piatek-Guziewicz, Michal Wozniakiewicz, Pawel Pasko, Justyna Dobrowolska-Iwanek, Aneta Wozniakiewicz, Aneta Targosz, Agata Ptak-Belowska, Urszula Szczyrk, Malgorzata Strzalka, Pawel Zagrodzki, Malgorzata Zwolinska-Wcislo
Summary: There is a close relationship between intestinal inflammation and nutrition in patients with inflammatory bowel disease (IBD). Patients with active IBD have poor nutritional status, reduced levels of short-chain fatty acids, and altered expression of tight junction proteins in the intestine.
